Invivyd Names Chairman Marc Elia as CEO, Grants 10.7M Options, and Adds New Director
IVVD sits 76% above its 52-week low of $0.528.
Summary
Invivyd appointed Chairman Marc Elia as CEO with a 10.7M-share option grant and added Ian Sheffield to its board, while signaling VYD2311 study results are expected around the end of Q3 2026.
Key Events · Executive and Board Changes · IVVD
-
Marc Elia Appointed CEO
Effective August 30, 2026, Chairman Marc Elia assumed the role of CEO, replacing William Duke Jr. as principal executive officer. His compensation includes a $750,000 base salary, a 70% target bonus, and a $500,000 sign-on bonus.
-
10.7M Option Grant to New CEO
Mr. Elia received an option to purchase 10,700,000 shares at the August 28, 2026 closing price, vesting over four years with 25% on the first anniversary and monthly thereafter.
-
New Independent Director Added
Ian Sheffield, founder of North Country Holdings, joined the board effective August 30, 2026, and received 100,000 stock options vesting over three years.
-
VYD2311 Data Readout Expected Q3 2026
The press release states top-line data from the DECLARATION and LIBERTY Phase 3 studies is expected around the end of Q3 2026, with further updates within weeks.
Analysis · IVVD · Life Sciences
Effective August 30, 2026, Invivyd has appointed its Chairman, Marc Elia, as CEO, succeeding William Duke Jr. as principal executive officer. The compensation package includes a $750,000 base salary, a 70% target bonus, a $500,000 sign-on bonus, and an option to purchase 10.7 million shares—a substantial equity grant for a company with a market cap near $281 million. The board also added Ian Sheffield as an independent director and granted him 100,000 options. The press release reiterates that top-line data from the VYD2311 DECLARATION and LIBERTY studies is expected around the end of Q3 2026, with further updates within weeks. This leadership change comes as the company faces going-concern doubt, a Nasdaq delisting notice, and the loss of its only authorized product's EUA—making the new CEO's strategic direction and the upcoming clinical data readout critical for the company's survival.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVVD was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $281.5M. The 52-week trading range was $0.53 to $3.07. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.